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Editors: Anton N. Sidawy and Bruce A. PerlerA multicenter, randomized, controlled trial of totally
percutaneous access versus open femoral exposure for
endovascular aortic aneurysm repair (the PEVAR trial)
Peter R. Nelson, Zvonimir Kracjer, Nikhil Kansal, Vikram Rao,
Christian Bianchi, Homayoun Hashemi, Paul Jones, J.
Michael Bacharach
Objective: The ﬁrst multicenter randomized controlled trial
was designed and conducted to assess the safety and
effectiveness of totally percutaneous endovascular aortic
aneurysm repair (PEVAR) with use of a 21F endovascular
stent graft system and either an 8F or 10F suture-mediated
closure system (the PEVAR trial, NCT01070069). A non-
inferiority trial design was chosen to compare percutaneous
access with standard open femoral exposure.
Methods: Between 2010 and 2012, 20 U.S. institutions
participated in a prospective, Food and Drug Admin-
istrationeapproved randomized trial to evaluate percuta-
neous femoral artery access and closure by a “preclose”
technique in conjunction with endovascular abdominal
aortic aneurysm repair. A total of 151 patients were allo-
cated by a 2:1 design to percutaneous access/closure (n =
101) or open femoral exposure (n = 50 [FE]). PEVAR pro-
cedures were performed with either the 8F Perclose Pro-
Glide (n = 50 [PG]) or the 10F Prostar XL (n = 51 [PS]) closure
devices. All endovascular abdominal aortic aneurysm repair
procedures were performed with the Endologix 21F proﬁle
(outer diameter) sheath-based system. Patients were
screened by computed tomography with three-dimensional
reconstruction and independent physician review for ana-
tomic suitability and adequate femoral artery anatomy for
percutaneous access. The primary trial end point (treatment
success) was deﬁned as procedural technical success and
absence of major adverse events and vascular complications
at 30 days. An independent access closure substudy eval-
uated major access-related complications. Clinical utility
and procedural outcomes, ankle-brachial index, blood lab-
oratory analyses, and quality of life were also evaluated
with continuing follow-up to 6 months.
Results: Baseline characteristics were similar among groups.
Procedural technical success was 94% (PG), 88% (PS), and
98% (FE). One-month primary treatment success was 88%
(PG), 78% (PS), and 78% (FE), demonstrating noninferiority vs
FE for PG (P = .004) but not for PS (P = .102). Failure rates in
the access closure substudy analyses demonstrated non-
inferiority of PG (6%; P = .005), but not of PS (12%; P = .100), vs
FE (10%). Compared with FE, PG and PS yielded signiﬁcantly*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(14)00172-5shorter times to hemostasis and procedure completion and
favorable trends in blood loss, groin pain, and overall quality
of life. Initial noninferiority test results persist to 6 months,
and no aneurysm rupture, conversion to open repair, device
migration, or stent graft occlusion occurred.
Conclusions: Among trained operators, PEVAR with an
adjunctive preclose technique using the ProGlide closure
device is safe and effective, with minimal access-related
complications, and it is noninferior to standard open fem-
oral exposure. Training, experience, and careful application
of the preclose technique are of paramount importance in
ensuring successful, sustainable outcomes.Results of endovascular repair of infrarenal aortic
aneurysms using the Endurant stent graft
Herman J.A. Zandvoort, Frederico Bastos Gonçalves, Hence
J.M. Verhagen, Debora A.B.Werson, Frans L. Moll, Jean-Paul
P.M. de Vries, Joost A. van Herwaarden
Objective: Recent reports showed that the Endurant stent
graft (Medtronic Cardiovascular, Santa Rosa, Calif) is safe
and effective for endovascular repair of abdominal aortic
aneurysms (AAAs). However, due to its relatively recent
introduction, only short-term follow-up data are available.
This study presents the 4-year results using this device.
Methods: All clinical data, including detailed anatomic
information of the ﬁrst 100 consecutive patients treated
with the Endurant stent graft for an infrarenal AAA in three
Dutch high-volume hospitals, were prospectively collected.
Computed tomography angiography was routinely per-
formed before the procedure, 1 month, and at 1 year
post-endovascular aneurysm repair. Thereafter, the imaging
modality during yearly follow-up was individualized (duplex
ultrasound imaging or computed tomography angiography).
Patients were classiﬁed as within or outside the instructions
for use (IFU) for analysis. Study end points were primary
clinical success, overall and AAA-related mortality, and sac
morphology changes and endoleak during follow-up. Esti-
mates were obtained using Kaplan-Meier plots.
Results: The study included 100 consecutive patients (88
men) with a median age of 74 years (interquartile range
[IQR], 67-79 years) and median AAA diameter of 58 mm
(IQR, 55-65 mm), between December 2007 and March
2009. Twenty patients (20%) were treated outside the IFU
(18, outside proximal neck IFU, one outside iliac IFU, and
one outside both IFUs). Median follow-up was 48 months
(IQR, 36-53 months), and no patients were lost. One con-
tained rupture was observed after 1.5 months due to graft
infection. No patients had graft migration. Two type Ia
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were found. Primary clinical success was 97%, 90%, 84%
and 77% at 1, 2, 3, and 4 years, respectively. Primary clinical
success was comparable for patients treated within or
outside IFU (P = .20), although both patients outside iliac
IFU needed a secondary iliac intervention. Over time,
maximum aneurysm diameter decreased 5 mm, remained
stable, and increased 5 mm in 58%, 32%, and 10% of the
patients, respectively. All-cause mortality was 20% at
4 years, with a 3% AAA-related mortality.
Conclusions: The 4-year follow-up data of the Endurant stent
graft for AAA treatment shows its use results in a low AAA-
related mortality with adequate prevention of rupture or
aneurysm growth. Although patients with very challenging
anatomy were treated in our series, primary clinical success
rates were comparable for patients treated within and out-
side the IFU. However, both patients outside the iliac IFU
needed a secondary iliac intervention. The knowledge of the
present results may aid in improving outcomes in the future.Effect of antiﬁbrinolytic therapy with tranexamic acid on
abdominal aortic aneurysm shrinkage after endovascular
repair
Atsushi Aoki, Takanori Suezawa, Shu Yamamoto, Kenji
Sangawa, Hiroyuki Irie, Nobuhiro Mayazaki, Satoshi Kami-
hira, Terutoshi Yamaoka
Objective: The long-term outcomes of endovascular
abdominal aortic aneurysm repair (EVAR) remain to be
determined, but patients with aneurysm shrinkage after
EVAR appear to have a good prognosis. We previously
observed that antiplatelet therapy is a risk factor for lack of
aneurysm shrinkage, a ﬁnding suggesting that coagulation
and ﬁbrinolysis play roles in shrinkage. We therefore stud-
ied the effect of antiﬁbrinolytic therapy with tranexamic
acid (TXA) on aneurysm shrinkage after EVAR.
Methods: FromMay 2007 toMay 2012, EVARwas performed
in 187 patients, 165 of whom had an enhanced computed
tomographic evaluation 6 months after their procedure. Six
of the 165 patients were excluded from the study because
they had a type Ia endoleak or coil embolization to treat a
type II endoleak6months after EVAR. Of the remaining 159
patients, 110 underwent EVAR before we started to use TXA
in our centers. TXA therapy (1500 mg/d for 6 months) began
in January 2011, and 48 patients completed the treatment
regimen. Patients not treated with TXA were compared with
those given TXA. Analyses to identify risk factors for lack of
aneurysm shrinkage were performed.
Results: No patient had a thromboembolic event. There
were no signiﬁcant differences between the no-TXA and
TXA groups in demographics, aneurysm characteristics,
prosthesis implanted, type II endoleak occurrence during
EVAR or 1 or 6 months afterward, or aneurysm shrinkage at
1 month. However, at 6 months after EVAR, the TXA group
had signiﬁcantly greater aneurysm shrinkage (P = .035) and
a signiﬁcantly higher percentage of patients with >4 mm inshrinkage (P = .010). Multiple regression analysis showed
aneurysm diameter, type II endoleak 6 months after EVAR,
and TXA treatment were independently associated with
aneurysm shrinkage or lack of shrinkage.
Conclusions: Antiﬁbrinolytic therapy with TXA was asso-
ciated with aneurysm shrinkage after EVAR. Studies to
identify the dosage of TXA that is optimally safe and
effective in this application, as well as investigations of the
best timing and route (parenteral vs oral) for TXA admin-
istration, are warranted.A limited and customized follow-up seems justiﬁed after
endovascular abdominal aneurysm repair in octogenarians
Linda Visser, Robert A. Pol, Ignace F.J. Tielliu, Jan J.A.M. van
den Dungen, Clark J. Zeebregts
Objective: The objective of this study was to determine
whether long-term follow-up after endovascular aneurysm
repair (EVAR) is justiﬁed in octogenarians.
Methods: Between September 1996 and October 2011, all
patients, including octogenarians, treated for an abdominal
aortic aneurysm (AAA) by EVARwere included in a prospective
database. Patients older than80 years andwith a nonruptured
infrarenal aneurysm treated electively or urgently were
included in the study (study group [SG]). Patients with rup-
tured aneurysms and patients who died during surgery or
within the ﬁrst postoperative month were excluded from
further analysis. The control group (CG) consisted of patients
younger than 80 years,matched for gender andAAAdiameter.
All patients were evaluated 4 to 8 weeks after EVAR and then
annually thereafter. Follow-up data were complemented by
reviewof the computerizedhospital registry and charts andby
contact of the patient's general practitioner or referring hos-
pital. Primary outcomes were stent- or aneurysm-related
complications and interventions. Secondary outcomes were
additional surgical complications and patient survival.
Results: A total number of 193 patients (SG, n = 97; CG, n =
96) were included for analysis. Median age was 80 years, and
88.6% were male. Median follow-up time was 33.6 months
(interquartile range [IQR], 12.9-68.3). Stent- and procedure-
related postoperative complications were comparable
between groups (SG, 41.2%; CG, 39.6%; P = .82). Median time
to complication was 2.3 months (IQR, 0.2-19.4) in the SG
compared with 18.1 months (IQR, 6.8-50.5) in the CG. The 2-
year complication-free survival rates were 58% (SG) and 60%
(CG). Interventions were performed signiﬁcantly less fre-
quently in octogenarians (SG, 8.2%; CG, 19.8%; P < .05).
Median time to intervention was 11.1months (IQR, 2.0-31.0)
in the SG compared with 54.3 months (IQR, 15.0-93.2) in the
CG.The 2-year intervention-free survival rates were 90% (SG)
and 92% (CG). During follow-up, 98 patients died (SG, n = 54;
CG, n = 44); median time to death was 31.8 months (IQR,
13.3-66.0) in the SG compared with 44.4 months (IQR, 15.0-
77.7) in the CG. One aneurysm-related death occurred in the
CG.The 2- and 5-year survival rates were 71% and 32% for the
SG compared with 77% and 66% for the CG (P < .05).
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procedures and AAA-related deaths in octogenarians, long-
term and frequent follow-up after EVAR seems ques-
tionable. An adapted and shortened follow-up seems war-
ranted in this patient group.Durability of eversion carotid endarterectomy
Enzo Ballotta, Antonio Toniato, Giuseppe Da Giau, Renata
Lorenzetti, Anna Da Roit, Claudio Baracchini
Objective: Carotid endarterectomy (CEA) remains the gold
standard for treating carotid disease in selected sympto-
matic and asymptomatic patients, though carotid angio-
plasty and stenting has emerged as a safe alternative. The
aim of this study was to assess the durability of CEA in a
large series of patients followed up according to a strict
clinical and ultrasonographic protocol.
Methods: Over a 23-year period (1990-2012) a total of 1773
patients (1251 men and 522 women) with a mean age of
75.2 years (range, 31 to 96 years) who underwent 2007
consecutive primary eversion CEAs performed by the same
surgeon under general anesthesia with electroencephalo-
graphic monitoring and selective shunting were pro-
spectively followed up with ultrasonography at 1, 6, and
12 months, then yearly. A long-term follow-up (median,
11.2 years; mean, 12.9 years) was obtained for 1680
patients (94.8%). End points were perioperative (30-day)
stroke and death and late carotid restenosis/occlusion rates.
Results: More than two in three of the lesions (1446 of
2007, 72.1%) were symptomatic at the time of surgery, with
a 25% rate of preoperative stroke. Preoperative antiplatelet
or anticoagulant therapy was used by 1675 patients
(94.4%), whereas 918 (51.8%) were receiving statin treat-
ment. Overall, there were eight (0.4%) perioperative strokes
and no deaths. During the follow-up, there were nine
(0.47%) asymptomatic late carotid restenoses (six moderate
[50%-69%] and three severe [70%]) and one (0.05%)
carotid occlusion. Nine patients (0.47%) had late ipsilateral
strokes, none of them related to restenosis/occlusion.
Overall, there were 159 late deaths (9.4%).
Conclusions: The results of this study show that eversion
CEA can be performed in symptomatic and asymptomatic
patients with an extremely low perioperative stroke/death
risk and a negligible incidence of late restenosis/occlusion,
thus assuring a persistently good protection against the risk
of cerebral ischemia.Preoperative smoking is associated with early graft failure
after infrainguinal bypass surgery
Shalini Selvarajah, James H. Black, Mahmoud B. Malas, Ying
Wei Lum, Brandon W. Propper, Christopher J. Abularrage
Objective: Smoking has been implicated as the single most
important risk factor for the development of peripheralarterial disease. Whereas previous studies have found poor
long-term outcomes in smokers undergoing lower extremity
bypass, there is a lack of consistent reports describing the
effects of persistent tobacco abuse on early outcomes after
infrainguinal bypass.
Methods: The American College of Surgeons National Sur-
gical Quality Improvement Program database from 2005 to
2011 was queried for primary infrainguinal bypasses. A
bivariate analysis was done to assess preoperative and
intraoperative risk factors for the primary outcome of 30-
day graft failure comparing active smokers with non-
smokers, deﬁned as patients who did not smoke within the
12 months before surgery. Multivariable logistic regression
was conducted to assess the independent association of
active smoking with graft failure.
Results: In 6614 (40.0%) active smokers and 9920 (60.0%)
nonsmokers, 16,534 infrainguinal bypasses were performed.
Active smokers were more likely to be younger, male, and of
nonwhite race and to have a history of chronic obstructive
pulmonary disease (P < .001, all). Nonsmokers were more
likely to be functionally dependent and had signiﬁcantly
more comorbidities (ie, hypertension, diabetes, obesity,
congestive heart failure, history of previous cardiac surgery
or intervention, and dialysis; P < .001, all). The presence of
critical limb ischemia was similar in both groups (53.1% of
active smokers vs 53.5% of nonsmokers; P = .61). More
nonsmokers received a tibial-level bypass than did active
smokers (47.8% vs 33.9%; P < .001). There was a trend
toward increased early graft failure in active smokers
compared with nonsmokers (5.3% vs 4.7%; P = .08). With
adjustment for other variables, especially bypass level and
graft type, there was an independent association between
active smoking and early graft failure (adjusted odds ratio,
1.21; 95% conﬁdence interval, 1.02-1.43; P = .03).
Conclusions: Although nonsmokers were signiﬁcantly older,
had more comorbidities, and required more distal revascula-
rization, active smokers still had an increased risk for devel-
opment of early graft failure. These results stress the need for
immediate smoking cessation before lower extremity bypass.
Further research is warranted to determine an optimal period
of abstinence among smokers with peripheral arterial disease
to reduce their risk for early graft failure.Current treatment of renal artery aneurysms may be too
aggressive
Jill Q. Klausner, Michael P. Harlander-Locke, Adam N.
Plotnik, Evan Lehrman, Brian G. DeRubertis, Peter F.
Lawrence
Objective: Most studies recommend repair of renal artery
aneurysms (RAAs) >2 cm in diameter in asymptomatic
patients, but other studies have suggested that their natural
history may be more benign. We hypothesized that rupture
and death in patients with asymptomatic RAAs is low and
that current recommendations for RAA treatment at 2 cm
may be too aggressive.
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tertiary care medical center from 2002 to 2012.
Results: Fifty-nine RAA were identiﬁed in 40 patients (mean
age at diagnosis, 56 years; male:female ratio, 17:23); 31
were saccular, 8 were fusiform, and 5 were bilobed. Twenty-
nine patients were asymptomatic; the remainder of
patients presented with hematuria (n = 4), abdominal pain
(n = 3), difﬁcult-to-control hypertension (n = 3), or ﬂank
pain (n = 2). Aneurysm location included the main renal
artery bifurcation (n = 35), main trunk (n = 7), primary
branch (n = 6), pole artery (n = 6), and secondary branch
(n = 1). Operative management of RAAs included vein patch
(n = 6), prosthetic patch (n = 4), primary repair (n = 3),
plication (n = 1), patch and implantation (n = 1), and ex vivo
repair (n = 1). Eight asymptomatic RAAs were treated sur-
gically (mean RAA diameter = 2.4  0.1 cm, range, 2-3 cm),
with the remaining 33 asymptomatic RAAs being managed
conservatively (mean RAA diameter = 1.4  0.1 cm, range,
0.6-2.6 cm). Mean hospital length of stay was 4 days, with
no late postoperative complications and 0% mortality. Non-
operated patients were followed for a mean of 36 
9 months, with no late acute complications and 0% mor-
tality. Mean RAA growth rate of patients with multiple
imaging studies was 0.60  0.16 mm/y.
Conclusions: The rate of aneurysm rupture and death in our
untreated RAA patients is zero, the growth rate is 0.60 
0.16 mm/y, and there were no adverse outcomes in
asymptomatic RAAs >2 cm that were observed. We may
currently be too aggressive in treating asymptomatic RAAs.Superﬁcialization of brachial artery as effective alternative
vascular access
Takashi Nakamura, Kotaro Suemitsu, Junichi Nakamura
Objective: The Japanese Society for Dialysis Therapy rec-
ommends superﬁcialization of the brachial artery (BA) as an
alternative vascular access (VA) technique in patients for
whom a conventional internal shunt (arteriovenous ﬁstula
[AVF] or arteriovenous graft) cannot be created. Although2% to 3% of Japanese hemodialysis patients undergo this
procedure, it is not well recognized worldwide. We report
here our experience with the procedure, as well as indica-
tions, durability, and morbidity.
Methods: The technique involves exposure of the BA and
ligation of the side branches, then ﬁxing it beneath the skin
at the upper arm. Cannulation of the BA is performed
2 weeks or more after surgery, and it is used as an outﬂow
route, with any vein in an upper extremity utilized for blood
return, including the hand if sites in the arm are not
accessible. We retrospectively reviewed our cases of
superﬁcialization of the BA for VA.
Results: From 2005 through 2008, a total of 24 patients (11
females [46%]; average age, 69 years [range, 39-84 years])
underwent superﬁcialization of the BA, of whom eight
(33%) had diabetes. The indications were (1) impaired car-
diac function (n = 13); (2) no other prospect for AVF or
patient refused prosthetic graft implantation (n = 5); (3)
severe upper extremity arterial disease or ischemic steal
syndrome requiring AVF closure (n = 3); (4) venous hyper-
tension with central vein occlusion (n = 2); and (5) repeated
AVF thrombosis due to heparin-induced thrombocytopenia
(n = 1). The mean follow-up period was 28 months. Serious
complications were seen in one patient with an infected
pseudoaneurysm formation associated with a BA puncture,
which necessitated BA ligation, while two patients required
an aneurysmectomy with reconstruction and one had
occlusion of the superﬁcialized BA, though no clinical
symptoms of hand ischemia developed. We also had difﬁ-
culty ﬁnding a vein for blood return in ﬁve patients. The rate
of superﬁcialized BA patency as a functioning VA was 95%
and 66% at 1 and 3 years, respectively.
Conclusions: Superﬁcialization of the BA was found to be a
simple and safe technique, with acceptable durability and
complication rate in selected Japanese hemodialysis
patients. We consider that this shuntless VA permits ade-
quate blood ﬂow and has theoretical advantages for some
patients, particularly those with impaired cardiac function,
though the availability of a return vein is a prerequisite for a
functioning VA.
